Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Novacyt (NYZ) Stock Price & Analysis

0 Followers

NYZ Stock Chart & Stats

€0.42€0.02(9.64%)
At close: 5:30 PM GMT+1
€0.5€1€1.5Mar 3Apr 11Feb 19Mar 6
Day’s Range
EUR 0.42 - EUR 0.42
52-Week Range
EUR 0.29 - EUR 0.97
Previous Close
EUR 0.38
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 31.14M
Enterprise Value
EUR 29.84M
Total Cash (Recent Filing)
EUR 8.88M
Total Debt (Recent Filing)
EUR 10.19M
Price to Earnings (P/E)
―
Beta
0.13
Next Earnings
Apr 29, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sustained Revenue Growth

Revenue growth has continued across three consecutive half-years, while the underlying business expanded even excluding the Southern Cross contribution. This indicates improving commercial traction and broader demand, providing a stronger base for future scale if growth remains balanced across regions and products.

Strategic Illumina Partnership

A five-year collaboration with Illumina provides a durable commercial and technical relationship with a major diagnostics platform. Successful delivery could support recurring project opportunities, strengthen Novacyt's credibility, and improve access to broader laboratory workflows over the medium term.

Product And Regulatory Expansion

IVDR approval removes a key market-access barrier for the DPYD assay and enables commercialization across Europe and other served markets. The product addresses chemotherapy dosing decisions, giving Novacyt a clinically relevant offering that can broaden its portfolio and customer reach.

Bears Say

Persistent Unprofitability

Novacyt remains deeply loss-making despite the revenue rebound, showing that current scale and pricing are insufficient to cover the cost base. Persistent operating losses limit internally funded investment, make execution more dependent on restructuring, and leave profitability as the central fundamental risk.

Ongoing Cash Burn

Negative operating and free cash flow have persisted across multiple years, indicating that growth is not yet converting into financial self-funding. Continued consumption reduces flexibility for product development and acquisitions, while the recent cash decline increases the importance of achieving the promised restructuring benefits.

Margin And RUO Pressure

The margin decline reflects a less favorable revenue mix, including lower-margin Southern Cross sales and reduced contribution from the high-margin Primerdesign business. RUO revenue also declined, weakening an important cash-generating stream and making the long-term margin target more dependent on execution.

Novacyt News

NYZ FAQ

What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.29 and its highest was €0.97 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €31.14M.
When is Novacyt’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Sep 30, 2026. The company reported -€0.093 earnings per share for the quarter.
Is Novacyt overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -€0.093 in its last earnings report. Following the earnings report the stock price went down -1.563%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in DE:NYZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology